Skip to main content
. Author manuscript; available in PMC: 2011 Jan 15.
Published in final edited form as: Clin Cancer Res. 2010 Jan 12;16(2):600–609. doi: 10.1158/1078-0432.CCR-09-1979

Figure 6. CR012 augments antiproliferative effects of paclitaxel in xenografts.

Figure 6

A. CR012 recognizes SLPI expression in OVCAR3 xenografts. Immunohistochemical staining with CR012 (right) or IgG2 isotype control (left) indicates specific staining. B. CR012 augments anticancer activity of paclitaxel. Median tumor volumes are plotted as a function of time. The combination of CR012 and paclitaxel yielded a T/C of 298% (p<0.001). Treatment started on day 1: IgG2 or CR012, 1 mg/kg by tail vein every 4 days × 4 doses; paclitaxel 7.5 mg/kg by tail vein every other day × 5 doses.